Key result
Myostatin pathway inhibition may enhance muscle function as a complementary approach in spinal muscular atrophy.
Why the study?
SMN-targeted treatments focus on motor neuron survival, leaving treated individuals with persistent muscle weakness, and understanding how muscle-targeted myostatin-inhibiting therapies can be incorporated into clinical practice is needed.
Does inhibition of the myostatin signaling pathway improve motor function in individuals with spinal muscular atrophy?
Does inhibition of the myostatin signaling pathway improve motor function in individuals with spinal muscular atrophy?
Myostatin signaling inhibition offers a potential complementary, muscle-targeted approach to improve motor function in patients with spinal muscular atrophy.
May support adjunctive myostatin inhibition in SMA; leaves open confirmation in randomized trials.
SMN-targeted disease-modifying treatments focus on motor neuron survival rather than muscle. Treated individuals nonetheless experience a range of persistent muscle weakness. Treatments that inhibit myostatin signaling represent a potential complementary pathway for direct muscle enhancement. In the evolving SMA treatment landscape, understanding how muscle-targeted treatment can be incorporated into clinical practice will facilitate individualized treatment decisions and identify outcomes that best encapsulate maintenance or improvement of motor function across the phenotypic spectrum of SMA.
No takes yet. Share an insight, caveat, or question.
Finkel et al. (2026) studied this question. Inhibition of the myostatin signaling pathway may provide a complementary approach to enhance muscle function in individuals with spinal muscular atrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: